The transcription factor, nuclear factor-sell (NF-KB) is known to playa major role in immune response, inflammation and, via apoptosis and proliferation, also in oncogenesis. Transcription of NFKB1, which encodes the subunit p50/pl05 of NF-KB, seems to be influenced by an insertion/deletion polymorphism in its promoter region. Accordingly, the goal of this study is to investigate whether this polymorphism can serve as a putative prognostic marker in patients with Squamous Cell Carcinomas of the Head and Neck region (HNSCC). The prognostic value of the -94ins/deIATTG NFKBI promoter polymorphism was analyzed in an unselected series of patients treated with curative intent for HNSCC, including all tumor stages with different therapeutical regimens. Genotyping was performed by means of pyrosequencing, using DNA from paraffin-embedded tissue samples from 364 patients with a median follow-up of 61 (2-143) months. The various genotypes were correlated with relapse-free and overall survival, as well as risk, compared to healthy volunteers. The NFKBI polymorphism was not related to risk of HNSCC. Kaplan-Meier curves revealed no significant association between the -94ins/deIATTG alleles and survival or disease progression of patients with HNSCC. In conclusion, the results suggest that the investigated NFKBI promoter polymorphism has no prognostic impact on risk or clinical course in HNSCC.
Nuclear factor-xls (NF-KB) is a major transcription regulator involved in inflammation, immune response, apoptosis, and cell proliferation. The activation of NF-KB, and consequently the enhanced expression of its target genes, has been proposed as a cardinal feature of carcinogenesis in a variety of malignancies (1-8). A functional insertion! deletion polymorphism (-94ins/deIATTG) in the promoter of NFKB 1, which encodes the subunit p50 of NF-KB, was found to be associated with several pathologies (6, (9) (10) (11) ), e.g. it was reported as risk factor of oral squamous cell carcinoma (OSCC) and as predictor of relapse-free survival in bladder cancer (11). Based on these findings, we analyzed the prognostic impact of this polymorphism in head and neck squamous cell carcinoma (HNSCC), a tumor entity for which novel biomarkers allowing a more precise prediction of prognosis and/or therapeutic response are desperately needed.
MATERIALS AND METHODS
The study group consisted of 364 Caucasian patients with HNSCC diagnosed and treated between 1995 and 200 I at the West German Cancer Center Essen (WTZE). Relevant c1inico-pathological data were extracted from the patients' files or collected by telephone interviews with the patients, their relatives, or doctors. The control group consisted of 307 healthy, ethnically matched blood donors described elsewhere (12) .
DNA was extracted from paraffin-embedded specimens. DNA extraction, polymerase chain reaction (PCR), and genotyping by pyrosequencing were performed as previously described in detail (6, 9, 12) . Genotyping results were confirmed by estimating the Hardy-Weinberg equilibrium (HWE) and re-genotyping of randomized selected samples. The study was strictly performed according to the Declaration of Helsinki and approved by the local Ethics Committee.
Case-control comparison of genotype frequencies and comparison of categorical data were examined by the X 2 test. Continuous variables were compared using the two-sided analysis of variance. Overall survival (OS) and relapse-free survival (RFS) dependent on genotypes were assessed using Kaplan-Meier plots and the log-rank test. Statistical significance was set at P<0.05. Power was calculated based on the hazard ratios (HR) published previously (11). All statistical analyses were performed using SPSS 14.0 (SPSS, Chicago, IL, USA), Graphpad Prism 4.0 (Graphpad Software, San Diego, CA, USA) or QUANTO 1.2.3 (13) .
RESULTS
Allele frequencies in patients and controls were equal (insertion 0.6, deletion 0.4). There was no statistically significant difference in genotype distributions (P=0.702). Neither case nor control genotypes diverged from HWE. Epidemiological data, as well as genotype distributions of all patients, are shown in Table 1 . Males were five times more often affected than females, but gender was not related to genotypes. Besides smoking habits (P=0.030), neither age, tumor site, American Joint Committee on Cancer (AJCC) tumor stage, grading, nor therapy were statistically significant associated with genotypes. Fig. 2 ).
DISCUSSION
HNSCC represents the sixth most prevalent neoplasm in the world. Despite fundamental advances in the treatment of HNSCC, the five-year survival rates still do not exceed 50%. Tumor volume, stage, and grading are currently still the most important factors predicting outcome. However, neither the clinical course nor the response to therapy can be satisfactorily predicted by these parameters. Reliable biomarkers allowing a more individualized approach to select the optimal treatment strategy (e.g. surgery, radiotherapy, chemoradiotherapy, new targeted drugs, or a combination ofthese modalities) are needed.
NF-KB is a transcription factor that is not only a key player in inflammation, but is also involved in cell survival, angiogenesis and apoptosis (14) (15) (16) . It is over-expressed in various tumor types promoting chemoresistance and/or. tumor progression (17) . In HNSCC, the role ofNF-KB is well established (18) . Up-regulation of NF-KB is often concordant with up-regulated cyclooxygenase-2 (COX-2) in HNSCC (19) (20) (21) . COX-2 expression in tumors can occur distinct from inflammation, but can also catalyze the synthesis ofprostaglandins creating an inflammatory microenvironment, and eventually lead to DNA damage caused by free radicals (22) . It has been shown that the inhibition of COX-2 suppresses tumor growth and proliferation in HNSCC cells ._-ti::.·. . r~·: (23). As COX-2 is a NF-KB target, the regulation of NF-KB might have an impact on its transcriptional modification.
One prominent subunit ofNF-KB, p50, is encoded by NFKB1. The insertion allele of a common insertion/deletion polymorphism (-94ins/delATTG) in the promoter of NFKB1 enhances binding of nuclear proteins; additionally, the reporter activity is increased on promoter constructs harboring the 4bp insertion (10) , and an association to an increased mRNA expression as compared to the deletion allele has been shown (6) . Recently, this polymorphism was described to be related to the risk of development of HNSCC of the oral cavity (11), and was suggested to be a marker for relapse-free survival in bladder cancer (6) . The results of the present study, however, showed no prognostic impact ofthe -94ins/ delATTG polymorphism on the risk for HNSCC, even though the study was estimated to have a power of more than 90% to demonstrate the published genotypedependent differences. This clearly shows the NFKB1 promoter polymorphism cannot be generally applied as a prognostic marker. It could act as a disease-specific marker in bladder cancer, as shown previously, but might be considerably limited in the conclusions that can be drawn from it in SCC of the head and neck. However, since the investigated variant seems to influence inflammatory processes (9) , the prognostic value of this variant should be tested in larger studies.
In conclusion, neither in HNSCC, nor in the different anatomical subsites, did the NFKB1 polymorphism prove to be a predictive marker for overall and relapse-free survival.
